Importance Rheumatoid arthritis (RA) occurs in about 5 per 1000 people and can lead to
severe joint damage and disability. Significant progress has been made over the past 2 …

C-reactive protein (CRP) is routinely assessed as a marker of systemic inflammation in
rheumatoid arthritis (RA). However, it is also an immune regulator that plays an important …

Drugs available for asthma treatment in the first decades of the 20th century
(sympathomimetic agents such as oral ephedrine, intravenous adrenaline, or inhaled …

Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis
(RA) but the balance of benefit and harm is still unclear. Methods The GLORIA …

Objective To develop a new evidence‐based, pharmacologic treatment guideline for
rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the …

Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation,
which affects approximately 1% of the population. The benefit of early recognition and …

Objectives Since the 2007 recommendations for the management of early arthritis have
been presented, considerable research has been published in the field of early arthritis …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …